Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
- PMID: 16827619
- PMCID: PMC2716009
- DOI: 10.1586/14760584.5.3.347
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Abstract
Neutralizing antibody induction is a key feature of many effective vaccines and is the only immune response that has proven to be capable of completely blocking AIDS virus infection in animal models. Unfortunately, the extensive genetic variability and complex immune-evasion strategies of HIV-1 have thwarted all attempts to date at eliciting an effective neutralizing antibody response with candidate HIV-1 vaccine immunogens. Recent advances in our understanding of how these evasion strategies operate, coupled with growing progress in unravelling the structure and immunobiology of the viral envelope glycoproteins, are contributing to novel immunogen designs to overcome the many barriers to inducing protective antibodies against HIV-1.
Figures



Similar articles
-
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Expert Rev Vaccines. 2006 Aug;5(4):579-95. doi: 10.1586/14760584.5.4.579. Expert Rev Vaccines. 2006. PMID: 16989638 Review.
-
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.J Virol. 1998 Dec;72(12):9656-67. doi: 10.1128/JVI.72.12.9656-9667.1998. J Virol. 1998. PMID: 9811699 Free PMC article.
-
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.Science. 1999 Jan 15;283(5400):357-62. doi: 10.1126/science.283.5400.357. Science. 1999. Retraction in: Science. 2002 May 10;296(5570):1025. doi: 10.1126/science.296.5570.1025b. PMID: 9888845 Retracted.
-
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.J Virol. 2018 Feb 12;92(5):e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1. J Virol. 2018. PMID: 29237847 Free PMC article.
-
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.Science. 1998 Jun 19;280(5371):1884-8. doi: 10.1126/science.280.5371.1884. Science. 1998. PMID: 9632381 Review.
Cited by
-
A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1.Nat Commun. 2021 Nov 9;12(1):6464. doi: 10.1038/s41467-021-26846-z. Nat Commun. 2021. PMID: 34753944 Free PMC article.
-
Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.J Virol. 2011 Jun;85(12):5825-39. doi: 10.1128/JVI.00154-11. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471242 Free PMC article.
-
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys.J Virol. 2008 Jun;82(11):5618-30. doi: 10.1128/JVI.02748-07. Epub 2008 Mar 26. J Virol. 2008. PMID: 18367534 Free PMC article.
-
Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.J Virol. 2011 Jun;85(11):5262-74. doi: 10.1128/JVI.02419-10. Epub 2011 Mar 23. J Virol. 2011. PMID: 21430056 Free PMC article.
-
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.J Virol. 2010 Jun;84(11):5637-55. doi: 10.1128/JVI.00105-10. Epub 2010 Mar 24. J Virol. 2010. PMID: 20335257 Free PMC article.
References
-
- Klausner R, Fauci A, Corey L, et al. Medicine. The need for a global vaccine enterprise. Science. 2003;5628:2036–2039. - PubMed
-
- Esparza J, Klausner RI The Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan. 2005;2:e25. - PubMed
-
- Derived from Statistics in Global Summary of the AIDS Epidemic, ‘AIDS Epidemic Update’ UNAIDS. World Health Organization; 2005. Dec,
-
- Letvin NL. Progress toward a HIV vaccine. Ann. Rev. Med. 2005;56:213–223. - PubMed
-
- Gandhi R, Walker B. Immunologic control of HIV-1. Ann. Rev. Med. 2002;53:149–172. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical